Drug Approval | March 06, 2023
Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
She was the CEO of Tata Insights and Quants a Division of the Tata Industries Ltd.
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
Rocuronium Bromide Injection is a neuromuscular blocking agent
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
The WHO - Global Center for Traditional Medicine will help member countries in taking enabling steps in their countries for strengthen education and practices of traditional mdicine
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Subscribe To Our Newsletter & Stay Updated
